Anakinra authorized to treat severe coronavirus disease 2019; Sepsis breakthrough or time to reflect?

IntroductionThe European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) announced conditions for using recombinant human interleukin-1 receptor antagonist (rhIL-1ra) to treat hospitalized patients with Coronavirus disease 2019 (COVID-19) and risk for progression. The...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Leland Shapiro, Sias Scherger, Carlos Franco-Paredes, Amal Gharamti, Andrés F. Henao-Martinez
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2023-10-01
coleção:	Frontiers in Microbiology
Assuntos:	anakinra COVID-19 sepsis cytokines cytokine storm inflammation
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fmicb.2023.1250483/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!